Khavinson Peptides: The Science Behind Bioregulators
Professor Vladimir Khavinson has published over 800 peer-reviewed papers, holds more than 200 patents, and has been researching bioregulator peptides for over 50 years. His work forms the entire evidence base for the bioregulator field — and it is largely unknown in Western research circles.
Research context. Khavinson's work is a legitimate body of peer-reviewed science, though it comes from a different research tradition than standard Western RCTs. Critical evaluation is appropriate. This article is educational.
Vladimir Khavinson is the Director of the St. Petersburg Institute of Bioregulation and Gerontology, a member of the Russian Academy of Sciences, and a professor with over 50 years of continuous research into peptide bioregulators. He began his career in the 1970s, initially working on behalf of the Soviet military and space programme to develop compounds that could preserve physiological performance under extreme conditions.
His core discovery — made in the mid-1970s — was that short peptide fractions extracted from various organs could restore the function of those organs when they were stressed or ageing. An extract from the thymus restored immune function; an extract from the pineal gland normalised circadian rhythms and melatonin production; an extract from brain tissue improved neural recovery after injury.
Over the following decades, Khavinson's group moved from complex tissue extracts to identifying the specific active di/tri/tetrapeptides within those extracts, then to synthesising pure versions of those peptides. The result is the family of "cytomax" compounds: Epitalon (synthetic pineal peptide), Thymalin (synthetic thymus peptide), Cortexin (complex cortical fraction), and others.
800+
Published papers
200+
Patents held
50+
Years of research
Key Studies
St. Petersburg Veterans Cohort (1973–2018)
The most cited Khavinson study. 266 subjects aged 60–80 followed for up to 12 years. Those receiving biannual Thymalin + Epitalon cycles showed 1.6–2.0x reduction in mortality compared to controls. Cancer incidence was reduced by approximately 40%. This is the data that underpins most bioregulator longevity claims.
Khavinson VKh, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters.
Epitalon and cancer incidence (2006)
Subjects receiving annual Epitalon cycles showed lower incidence of malignant neoplasms over a 15-year observation period compared to matched controls. Proposed mechanism: improved immune surveillance via NK cell activity and reduced DNA oxidative damage.
Anisimov VN et al. (2006). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.
Thymalin and immune restoration (1997)
Elderly subjects (65+) received 10-day Thymalin cycles for 6 years. Compared to controls, the treated group showed preserved T-cell counts, maintained NK cell activity, and reduced incidence of acute infections. The treated group also showed significantly lower mortality at the 6-year follow-up.
Morozov VG, Khavinson VKh (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol.
Cell culture and telomerase studies
Multiple in vitro studies demonstrate Epitalon's ability to activate telomerase in somatic cells, including human fetal fibroblasts. Cells treated with Epitalon show longer telomeres and extended replicative lifespan compared to untreated controls. This provides the mechanistic explanation for the in vivo longevity data.
Vaskova EA et al. Multiple cell culture and mouse model studies.
Russian journal publication
Most Khavinson research was published in Russian-language journals first, with English translations appearing years later. This created significant lag in Western awareness.
Cold War era research
The initial programme (1970s–1990s) was partly defence-funded and not widely accessible to Western researchers during the Soviet period.
Unfamiliar research tradition
Russian longevity research focuses on population-level mortality endpoints rather than the biomarker-focused RCT model preferred by Western regulators. This creates perception gaps about evidence quality.
Pharmaceutical economics
Khavinson's peptides are not patentable in most Western countries — the compounds are too structurally simple. Without patent protection, there is limited commercial incentive to fund large Western trials.
Epitalon — Research Grade
Khavinson's most studied synthetic peptide.
Peptide Detail Profiles
Bioregulator Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →